Recent advances in the cervical screening programme

Sarah Hawco; Margaret E. Cruickshank

doi:10.1111/1471-0528.17295

Recent advances in the cervical screening programme

Sarah Hawco^* (Corresponding Author), Margaret E. Cruickshank

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The UK National Screening Committee recommended high-risk human papillomavirus (hrHPV) primary screening in 2016, and it was introduced in England 3 years later, to increase the test sensitivity for cervical intraepithelial neoplasia, reducing the risk of developing cervical cancer. The 2018 call by the World Health Organization to eliminate cervical cancer as a public health measure supports primary HPV screening as both clinically effective and cost effective. In this commentary, we review the emerging evidence from primary HPV screening as pilot and replacement programmes establish themselves globally.

Original language	English
Pages (from-to)	131-134
Number of pages	4
Journal	BJOG: An International Journal of Obstetrics Gynaecology
Volume	130
Issue number	2
Early online date	6 Oct 2022
DOIs	https://doi.org/10.1111/1471-0528.17295
Publication status	Published - Jan 2023

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analysed in this study.

Additional supporting information can be found online in the Supporting Information section at the end of this article.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1471-0528.17295Licence: Unspecified

https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.17295Licence: Unspecified

Cite this

@article{262a4098995644ed8dbe571deca992c0,

title = "Recent advances in the cervical screening programme",

abstract = "The UK National Screening Committee recommended high-risk human papillomavirus (hrHPV) primary screening in 2016, and it was introduced in England 3 years later, to increase the test sensitivity for cervical intraepithelial neoplasia, reducing the risk of developing cervical cancer. The 2018 call by the World Health Organization to eliminate cervical cancer as a public health measure supports primary HPV screening as both clinically effective and cost effective. In this commentary, we review the emerging evidence from primary HPV screening as pilot and replacement programmes establish themselves globally.",

author = "Sarah Hawco and Cruickshank, {Margaret E.}",

year = "2023",

month = jan,

doi = "10.1111/1471-0528.17295",

language = "English",

volume = "130",

pages = "131--134",

journal = "BJOG: An International Journal of Obstetrics Gynaecology",

issn = "1471-0528",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "2",

}

TY - JOUR

T1 - Recent advances in the cervical screening programme

AU - Hawco, Sarah

AU - Cruickshank, Margaret E.

PY - 2023/1

Y1 - 2023/1

N2 - The UK National Screening Committee recommended high-risk human papillomavirus (hrHPV) primary screening in 2016, and it was introduced in England 3 years later, to increase the test sensitivity for cervical intraepithelial neoplasia, reducing the risk of developing cervical cancer. The 2018 call by the World Health Organization to eliminate cervical cancer as a public health measure supports primary HPV screening as both clinically effective and cost effective. In this commentary, we review the emerging evidence from primary HPV screening as pilot and replacement programmes establish themselves globally.

AB - The UK National Screening Committee recommended high-risk human papillomavirus (hrHPV) primary screening in 2016, and it was introduced in England 3 years later, to increase the test sensitivity for cervical intraepithelial neoplasia, reducing the risk of developing cervical cancer. The 2018 call by the World Health Organization to eliminate cervical cancer as a public health measure supports primary HPV screening as both clinically effective and cost effective. In this commentary, we review the emerging evidence from primary HPV screening as pilot and replacement programmes establish themselves globally.

U2 - 10.1111/1471-0528.17295

DO - 10.1111/1471-0528.17295

M3 - Comment/debate

C2 - 36168106

SN - 1471-0528

VL - 130

SP - 131

EP - 134

JO - BJOG: An International Journal of Obstetrics Gynaecology

JF - BJOG: An International Journal of Obstetrics Gynaecology

IS - 2

ER -

Recent advances in the cervical screening programme

Abstract

Data Availability Statement

UN SDGs

Access to Document

Fingerprint

Cite this